Skip to Content
Merck

Key Documents

View All Documentation

EHU107971

MISSION® esiRNA

targeting human GABARAPL1

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

NACRES:
NA.51
UNSPSC Code:
41105324
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

description

Powered by Eupheria Biotech

Quality Level

100

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

GGTCCCCGTGATTGTAGAGAAGGCTCCAAAAGCCAGGGTGCCTGATCTGGACAAGAGGAAGTACCTAGTGCCCTCTGACCTTACTGTTGGCCAGTTCTACTTCTTAATCCGGAAGAGAATCCACCTGAGACCTGAGGACGCCTTATTCTTCTTTGTCAACAACACCATCCCTCCCACCAGTGCTACCATGGGCCAACTGTATGAGGACAATCATGAGGAAGACTATTTTCTGTATGTGGCCTACAGTGATGAGAGTGTCTATGGGAAATGAGTGGTTGGAAGCCCAGCAGATGGGAGCACCTGGACTTGGGGGTAGGGGAGGGGTGTGTGTGCGCGACATGGGGAAAGAGGGTGGCTCCCACCGCAAGGAGACAGAAGGTGAAGACATCTAGAAACATTACACCACACACACCGTCATC

Ensembl | human accession no.

ENSG00000139112

NCBI accession no.

NM_031412

shipped in

ambient

storage temp.

−20°C

Gene Information

human ... GABARAPL1(23710)

General description

MISSION esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
XZU
OWU
QCS

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Minmin Fan et al.
Cell death & disease, 11(8), 635-635 (2020-08-18)
Breast cancer is a heterogeneous disease that includes different molecular subtypes. The basal-like subtype has a poor prognosis and a high recurrence rate, whereas the luminal-like subtype confers a more favorable patient prognosis partially due to anti-hormone therapy responsiveness. Here
Chih-Wen Shu et al.
Diagnostics (Basel, Switzerland), 11(2) (2021-03-07)
To investigate the association of autophagy-related gene expression with age-related macular degeneration (AMD). Patients with AMD were recruited for analysis by conjunctival impression cytology. mRNA was assessed by real-time polymerase chain reaction (RT-PCR) to evaluate whether the expression of 26